Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2009-12-08
2011-12-13
Canella, Karen (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C435S325000, C435S374000, C435S379000
Reexamination Certificate
active
08075882
ABSTRACT:
Adoptive immune cells obtained by a method including (a) obtaining mammalian antigen-presenting associated cells; (b) culturing the resulting cells from step (a) in a culture liquid contained in a culture vessel coated with a sugar chain-containing polymer; and (c) detaching the cells from step (b) by shaking the culture vessel without treating the cells with an enzyme and without using a cell detaching tool. A method for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, by administering the adoptive immune cells to a patient. A pharmaceutical composition for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, including the adoptive immune cells and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5851756 (1998-12-01), Steinman et al.
patent: 6121044 (2000-09-01), Peshwa et al.
patent: 6642050 (2003-11-01), Goto et al.
patent: 2006/0177420 (2006-08-01), Felzmann
patent: 05-041983 (1993-02-01), None
patent: 08-317786 (1996-12-01), None
patent: 2001-520509 (2001-10-01), None
patent: 2002-69001 (2002-03-01), None
patent: 2003-274923 (2003-09-01), None
patent: 2005-528899 (2005-09-01), None
patent: WO 97/03186 (1997-01-01), None
patent: WO 97/05239 (1997-02-01), None
patent: WO 03/100040 (2003-12-01), None
patent: WO 2004/024900 (2004-03-01), None
Mitchell et al (Journal of Clinical Oncology, 2002, vol. 20, pp. 1075-1086).
Feili-Hairi et al (European Journal of Immunology, 2002, vol. 32, pp. 2021-2030).
Akhtar et al (Journal of Experimental Medicine, 1995, vol. 182, pp. 87-97).
Yee et al (PNAS, 2002, vol. 99. pp. 16168-16173).
Panelli et al (Journal of Immunotherapy, 2000, vol. 23, pp. 487-498).
Brodie et al (Nature Medicine, 1999, vol. 5, pp. 34-41).
D. Choi et al, “Dendritic Cell-based Vaccines in the Setting of Peripheral Blood Stem Cell Transplantation: CD34+Cell-depleted Mobilized Peripheral Blood Can Serve as a Source of Potent Dendritic Cells,”Clin. Cancer Res., vol. 4, pp. 2709-2716, Nov. 1998.
F.J. Hsu et al, “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic celss,”NAT. MED., vol. 2, No. 1, pp. 52-58, Jan. 1996.
M. Takamizawa et al, “Cellular and Molecular Basis of Human yδ T Cell Activation”,J. Clin Invest., vol. 95, pp. 296-303, Jan. 1995.
V.L. Reichardt et al, “Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma-a Feasiblitity Study,”Blood, vol. 93, No. 7, pp. 2411-2419, Apr. 1999.
J. Wang et al, “Eliciting T Cell Immunity Against Poorly Immunogenic Tumors by Immunization with Dendritic Cell-Tumor Fusion Vaccines,”J. Immunol., vol. 161, pp. 5516-5524, 1998.
M.A. Morse et al, “A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen,”Clin. Cancer Res., vol. 5, pp. 1331-1338, Jun. 1999.
R.M. Steinman et al, “Dendritic Cell Development and Maturation”,Adv. Exp. Med., pp. 1-6., (1997).
R.J. Hodes et al, “Cellular and genetic control of antibody responses in vitro,”Eur. J. Immunol., vol. 7, pp. 892-897, (1977).
Jos W.M. Van Der Meer, “Culture of Mononuclear Phagocytes on a Teflon Surface to Prevent Adherence,”J. Exp. Med., vol. 147, pp. 271-276, (1978).
Jos. W.M. Van Der Meer, “Suspension Cultures of Mononuclear Phagocytes in the Teflon Culture Bag,”Cell. Immunol., vol. 42, pp. 208-212 (1979).
English-language International Preliminary Report on Patentability dated Nov. 14, 2006 and Written Opinion of the International Searching Authority, of International Application PCT/JP2004/006599 filed May 11, 2004; Applicants: Shukokai Incorporated et al.
Hirose et al., “Regulation of Asialoglycoprotein Receptor Expression in the Proliferative State of Hepatocytes,”Biochemical and Biophysical Research Communications, 287 (2001) 675-681.
Ishida et al., “Cell Adhesion Aside from Integrin System Can Abrogate Anoikis in Rat Liver Cells by Down-regulation of FasL expression, not by Activation of PI-3K/Akt and ERK Signaling Pathway,”Biochemical and Biophysical Research Communications, 300 (2003) 201-208.
Na et al., “Conjuation of Arg-Gly-Asp (RGD) Sequence in Copolymer Bearing Sugar Moiety for Insulinoma Cell Line (MIN6) Culture,”Biosci. Biotechnol. Biochem., 65(6), 1284-1289, (2001).
Japanese Office Action (Notification of Reasons for Rejection) dated Dec. 8, 2009 for JP 2006-512905.
Goto Mitsuaki
Hasumi Kenichiro
Imaizumi Akira
Iwama Masamichi
Canella Karen
Holtz Holtz Goodman & Chick PC
JSR Corporation
Shukokai Incorporated
LandOfFree
Adoptive immune cells for tumor vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adoptive immune cells for tumor vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adoptive immune cells for tumor vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265898